CN104918955B - Fcγ受体IIB变体 - Google Patents

Fcγ受体IIB变体 Download PDF

Info

Publication number: CN104918955B
Authority: CN; China
Prior art keywords: seq; protein; nucleic acid; host cell; cells
Prior art date: 2012-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201380056738.3A

Other languages

English (en)

Chinese (zh)

Other versions

CN104918955A (zh

Inventor

P·松德尔曼

D·特米尔

T·波尔

R·温特

U·雅各布

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Suppremol GmbH

Original Assignee

Suppremol GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-30

Filing date

2013-10-30

Publication date

2018-10-09

2013-10-30 Application filed by Suppremol GmbH filed Critical Suppremol GmbH

2015-09-16 Publication of CN104918955A publication Critical patent/CN104918955A/zh

2018-10-09 Application granted granted Critical

2018-10-09 Publication of CN104918955B publication Critical patent/CN104918955B/zh

Status Active legal-status Critical Current

2033-10-30 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)

CN201380056738.3A 2012-10-30 2013-10-30 Fcγ受体IIB变体 Active CN104918955B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13/663,527		2012-10-30
US13/663,527 US10028998B2 (en)	2012-10-30	2012-10-30	Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en)	2012-10-30	2013-10-30	Fc gamma receptor iib variants

Publications (2)

Publication Number	Publication Date
CN104918955A CN104918955A (zh)	2015-09-16
CN104918955B true CN104918955B (zh)	2018-10-09

Family

ID=49679480

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201380056738.3A Active CN104918955B (zh)	2012-10-30	2013-10-30	Fcγ受体IIB变体

Country Status (27)

Country	Link
US (1)	US10028998B2 (2)
EP (1)	EP2914624B1 (2)
JP (2)	JP6423351B2 (2)
KR (1)	KR102170674B1 (2)
CN (1)	CN104918955B (2)
AU (1)	AU2013340831B2 (2)
BR (1)	BR112015008815A2 (2)
CA (1)	CA2887164C (2)
CL (1)	CL2015001127A1 (2)
DK (1)	DK2914624T3 (2)
EA (1)	EA033437B9 (2)
ES (1)	ES2628049T3 (2)
HR (1)	HRP20170894T1 (2)
HU (1)	HUE032786T2 (2)
IL (1)	IL238528A (2)
IN (1)	IN2015DN03206A (2)
LT (1)	LT2914624T (2)
MX (1)	MX359802B (2)
MY (1)	MY173686A (2)
NZ (1)	NZ706884A (2)
PH (1)	PH12015500771B1 (2)
PL (1)	PL2914624T3 (2)
PT (1)	PT2914624T (2)
RS (1)	RS56075B1 (2)
SG (1)	SG11201502749VA (2)
SI (1)	SI2914624T1 (2)
WO (1)	WO2014068012A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10669324B2 (en)	2012-10-30	2020-06-02	Suppremol Gmbh	Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en)	2012-10-30	2018-07-24	Suppremol Gmbh	Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) *	2013-04-26	2014-10-29	SuppreMol GmbH	Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en)	2013-08-16	2015-02-18	SuppreMol GmbH	Novel anti-FcyRIIB IgG-type antibody
NZ719745A (en) *	2013-10-16	2018-10-26	Suppremol Gmbh	Soluble fc gamma receptor for treatment of autoimmune bullous diseases
JP6710451B2 (ja) *	2016-03-31	2020-06-17	東ソー株式会社	改変型組換えＦｃγＲＩＩｂ
WO2020002252A1 (de) *	2018-06-25	2020-01-02	Basf Coatings Gmbh	Verfahren zur herstellung einer optimierten beschichtung und mittels dieses verfahrens erhältliche beschichtung
CN111454914A (zh) *	2019-01-18	2020-07-28	嘉兴安宇生物科技有限公司	一种腺病毒快速纯化方法
KR20250122541A (ko)	2022-10-25	2025-08-13	사이즈믹 테라퓨틱, 인코포레이티드.	변이체 IgG FC 폴리펩티드 및 그 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050002924A1 (en) *	2001-11-22	2005-01-06	Robert Huber	Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III
CN1867583A (zh) *	2003-05-02	2006-11-22	赞科股份有限公司	优化的Fc变体及其产生方法
EP1870442A1 (en) *	2006-06-19	2007-12-26	DSMIP Assets B.V.	Air drying resin and composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3626187B2 (ja)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
CA2225460A1 (en)	1995-06-23	1997-01-09	Winston Campbell Patterson	Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en)	1997-09-17	2005-02-01	Human Genome Sciences, Inc.	Antibody to an IL-17 receptor like protein
EP1006183A1 (en)	1998-12-03	2000-06-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Recombinant soluble Fc receptors
NZ547629A (en)	2003-11-26	2009-08-28	Max Planck Gesellschaft	Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
EP1960427B1 (en)	2005-12-13	2011-02-23	SuppreMol GmbH	Multimeric fc receptor polypeptides
EP1870422A1 (en)	2006-06-20	2007-12-26	SuppreMol GmbH	Means for the treatment of diseases characterized by an excessive immune reaction
EP2623112B1 (en)	2008-06-27	2015-03-04	Zymogenetics, Inc.	Soluble hybrid Fc gamma receptors and related methods
US10669324B2 (en)	2012-10-30	2020-06-02	Suppremol Gmbh	Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en)	2012-10-30	2018-07-24	Suppremol Gmbh	Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

2012
- 2012-10-30 US US13/663,527 patent/US10028998B2/en active Active
2013
- 2013-10-30 EP EP13798258.3A patent/EP2914624B1/en active Active
- 2013-10-30 BR BR112015008815A patent/BR112015008815A2/pt not_active Application Discontinuation
- 2013-10-30 CN CN201380056738.3A patent/CN104918955B/zh active Active
- 2013-10-30 MX MX2015005266A patent/MX359802B/es active IP Right Grant
- 2013-10-30 IN IN3206DEN2015 patent/IN2015DN03206A/en unknown
- 2013-10-30 PT PT137982583T patent/PT2914624T/pt unknown
- 2013-10-30 DK DK13798258.3T patent/DK2914624T3/en active
- 2013-10-30 NZ NZ706884A patent/NZ706884A/en unknown
- 2013-10-30 HR HRP20170894TT patent/HRP20170894T1/hr unknown
- 2013-10-30 EA EA201590845A patent/EA033437B9/ru not_active IP Right Cessation
- 2013-10-30 JP JP2015538506A patent/JP6423351B2/ja active Active
- 2013-10-30 SI SI201330679A patent/SI2914624T1/sl unknown
- 2013-10-30 RS RS20170593A patent/RS56075B1/sr unknown
- 2013-10-30 HU HUE13798258A patent/HUE032786T2/en unknown
- 2013-10-30 PL PL13798258T patent/PL2914624T3/pl unknown
- 2013-10-30 AU AU2013340831A patent/AU2013340831B2/en active Active
- 2013-10-30 LT LTEP13798258.3T patent/LT2914624T/lt unknown
- 2013-10-30 SG SG11201502749VA patent/SG11201502749VA/en unknown
- 2013-10-30 CA CA2887164A patent/CA2887164C/en active Active
- 2013-10-30 ES ES13798258.3T patent/ES2628049T3/es active Active
- 2013-10-30 MY MYPI2015001106A patent/MY173686A/en unknown
- 2013-10-30 WO PCT/EP2013/072741 patent/WO2014068012A1/en not_active Ceased
- 2013-10-30 KR KR1020157013516A patent/KR102170674B1/ko active Active
2015
- 2015-04-07 PH PH12015500771A patent/PH12015500771B1/en unknown
- 2015-04-29 IL IL238528A patent/IL238528A/en active IP Right Grant
- 2015-04-29 CL CL2015001127A patent/CL2015001127A1/es unknown
2018
- 2018-08-09 JP JP2018149864A patent/JP2018186833A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050002924A1 (en) *	2001-11-22	2005-01-06	Robert Huber	Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III
CN1867583A (zh) *	2003-05-02	2006-11-22	赞科股份有限公司	优化的Fc变体及其产生方法
EP1870442A1 (en) *	2006-06-19	2007-12-26	DSMIP Assets B.V.	Air drying resin and composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. Sondermann et al.Human Fcγ Receptor IIb Expressed in Escherichia coli Reveals IgG Binding Capability.《Biological Chemistry》.1999,第380卷(第6期), *
P.Sondermann et al.Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution.《The EMBO Journal》.1999,第18卷(第5期), *

Also Published As

Publication number	Publication date
IN2015DN03206A (2)	2015-10-02
SG11201502749VA (en)	2015-05-28
RS56075B1 (sr)	2017-10-31
EA033437B1 (ru)	2019-10-31
IL238528A0 (en)	2015-06-30
KR20150122621A (ko)	2015-11-02
DK2914624T3 (en)	2017-06-26
AU2013340831B2 (en)	2017-11-23
CA2887164C (en)	2020-12-29
JP6423351B2 (ja)	2018-11-14
EA201590845A1 (ru)	2015-08-31
CA2887164A1 (en)	2014-05-08
IL238528A (en)	2017-07-31
MY173686A (en)	2020-02-15
JP2016503289A (ja)	2016-02-04
HRP20170894T1 (hr)	2017-09-08
NZ706884A (en)	2019-05-31
HK1209765A1 (en)	2016-04-08
US20140120080A1 (en)	2014-05-01
LT2914624T (lt)	2017-06-26
BR112015008815A2 (pt)	2017-11-21
PH12015500771A1 (en)	2015-06-08
EP2914624A1 (en)	2015-09-09
MX359802B (es)	2018-10-10
CL2015001127A1 (es)	2015-12-18
HUE032786T2 (en)	2017-10-30
WO2014068012A1 (en)	2014-05-08
KR102170674B1 (ko)	2020-10-28
PT2914624T (pt)	2017-06-07
CN104918955A (zh)	2015-09-16
JP2018186833A (ja)	2018-11-29
US10028998B2 (en)	2018-07-24
EA033437B9 (ru)	2020-03-19
PH12015500771B1 (en)	2018-12-14
PL2914624T3 (pl)	2017-09-29
ES2628049T3 (es)	2017-08-01
MX2015005266A (es)	2015-10-26
EP2914624B1 (en)	2017-03-15
AU2013340831A1 (en)	2015-04-30
SI2914624T1 (sl)	2017-07-31

Legal Events

Date	Code	Title
2015-09-16	PB01	Publication
2015-12-02	C10	Entry into substantive examination
2015-12-02	SE01	Entry into force of request for substantive examination
2018-10-09	GR01	Patent grant
2018-10-09	GR01	Patent grant

Publication	Publication Date	Title
CN104918955B (zh)	2018-10-09	Fcγ受体IIB变体
KR101516023B1 (ko)	2015-04-30	눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법
CN104968795B (zh)	2021-07-20	增强蛋白表达的多肽
TWI795740B (zh)	2023-03-11	用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
JP7071288B2 (ja)	2022-05-18	Ｔ細胞調節多量体ポリペプチド及びその使用方法
JP6567506B2 (ja)	2019-08-28	低下した又はサイレント化したエフェクター機能を持つヘテロ多量体
JP2020039357A (ja)	2020-03-19	非シアル化抗炎症ペプチド
KR20190044029A (ko)	2019-04-29	변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
CN116970060A (zh)	2023-10-31	T细胞调节性多聚体多肽及其使用方法
US20130224238A1 (en)	2013-08-29	Gpcr as vaccines or for removing/inhibiting autoantibodies, toxins or ligands binding to the gpcr
US20230414777A1 (en)	2023-12-28	Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
TW200848071A (en)	2008-12-16	Immunoglobulin fusion proteins and methods of making
EP3224282A1 (en)	2017-10-04	Lysosomal targeting and uses thereof
US10669324B2 (en)	2020-06-02	Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US20150166609A1 (en)	2015-06-18	Fusion expression of g-protein coupled receptor
US20080188404A1 (en)	2008-08-07	Hybrid And Chimeric Polypeptides That Regulate Activation Of Complement
HK1209765B (en)	2018-02-15	Fc gamma receptor iib variants
Zhang	2021	Structural-Based Study of Intact Human Particulate Guanylyl Cyclase Receptor A (pGC-A) and Biophysical Characterization
WO2024006576A1 (en)	2024-01-04	Mhc class ii protein constructs
WO2026050634A1 (en)	2026-03-05	Butyrophilin a2 for inhibition of b cell activation and/or for prolonged humoral suppression or humoral tolerance
JP2026508395A (ja)	2026-03-10	自己免疫及び炎症の処置のためのブチロフィリンａ２及び関連アイソフォーム
Plewnia	2008	Biochemical and biophysical characterization of extrinsic and intrinsic modulators of the antigen transporter TAP